Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 DES: Executive Summary

2.1 DES Therapeutics Market Will Grow to $5.6B by 2026

2.2 DES Is a High Risk Indication for Drug Development

2.3 While New Therapeutics Enter the DES Market, Unmet Needs Persist

2.4 Significant Opportunities Remain Within the DES Market to Fulfill Unmet Needs

2.5 Newly Approved Therapeutics Will Improve Treatment Options for DES Patients

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Disease Classification

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods – Population

5.4.3 Forecast Assumptions and Methods – Total and Diagnosed Prevalent Cases of DES

5.4.4 Forecast Assumptions and Methods – Total and Diagnosed Prevalent Cases of DES by Severity

5.5 Epidemiological Forecast for DES (2016–2026)

5.5.1 Total Prevalent Cases of DES

5.5.2 Age-Specific Total Prevalent Cases of DES

5.5.3 Sex-Specific Total Prevalent Cases of DES

5.5.4 Total Prevalent Cases of DES by Severity

5.5.5 Diagnosed Prevalent Cases of DES

5.5.6 Diagnosed Prevalent Cases of DES by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment Guidelines

6.1.3 Clinical Practice

6.2 US

6.3 5EU

6.4 Japan

6.5 China

7 Competitive Assessment

7.1 Overview

7.2 Marketed Therapies and Artificial Tears for DES

7.3 Other Therapies

7.3.1 Autologous Serum

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 New Therapies for DES

8.3 Better Diagnostic Tools

8.4 Appropriate Clinical Trial Design

8.5 Simplified Dosing

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Promising Drugs in Early-Stage Development

9.3.1 Lacripep

9.3.2 Voclosporin (LX-214)

9.3.3 SHP-659

9.3.4 Dextenza (OTX-DP)

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Allergan

10.4 Santen

10.5 Shire

10.6 RegeneRx

10.7 Aldeyra

10.8 Sylentis

10.9 Sun Pharmaceutical

10.10 Novartis

10.11 Dompe

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.4.1 Key Opinion Leaders

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table 1: DES: Key Metrics in the 8MM

Table 2: Risk Factors and Comorbid Conditions Associated with DES

Table 3: Diagnostic Tests for DES

Table 4: Popular Validated Questionnaires for DES

Table 5: Treatment Guidelines for DES

Table 6: Country Profile – US

Table 7: Country Profile – 5EU

Table 8: Country Profile – Japan

Table 9: Country Profile – China

Table 10: Leading Treatments for DES, 2018

Table 11: Comparison of Therapeutic Classes in Development for DES, 2016–2026

Table 12: Key Companies in the DES Market in the 8MM, 2017

Table 13: Allergan’s DES Portfolio Assessment, 2018

Table 14: Santen’s DES Portfolio Assessment, 2018

Table 15: Shire’s DES Portfolio Assessment, 2018

Table 16: RegeneRx’s DES Portfolio Assessment, 2018

Table 17: Aldeyra’s DES Portfolio Assessment, 2018

Table 18: Sylentis’ DES Portfolio Assessment, 2018

Table 19: Sun Pharma’s DES Portfolio Assessment, 2018

Table 20: Novartis’ DES Portfolio Assessment, 2018

Table 21: Dompe’s DES Portfolio Assessment, 2018

Table 22: DES Market – Global Drivers and Barriers, 2016–2026

Table 23: Key Events Impacting Sales for DES in the US, 2016–2026

Table 24: DES Market – Drivers and Barriers in the US, 2016–2026

Table 25: Key Events Impacting Sales for DES in the 5EU, 2016–2026

Table 26: DES Market – Drivers and Barriers in the 5EU, 2016–2026

Table 27: Key Events Impacting Sales for DES in Japan, 2016–2026

Table 28: DES Market – Global Drivers and Barriers in Japan, 2016–2026

Table 29: Key Events Impacting Sales for DES in China, 2016–2026

Table 30: DES Market – Global Drivers and Barriers in China, 2016–2026

Table 31: Key Historical and Projected Launch Dates for DES

Table 32: Key Historical and Projected Patent Expiry Dates for DES

Table 33: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for DES in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period

Figure 3: Vicious Circle of DES

Figure 4: Tear Film Structure

Figure 5: Classification of DES

Figure 6: 8MM, Age-Standardized Total Prevalence of DES (%), Both Sexes, Ages ≥20 Years, 2016

Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES

Figure 8: 8MM, Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016

Figure 9: 8MM, Age-Specific Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016

Figure 10: 8MM, Sex-Specific Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016

Figure 11: 8MM, Diagnosed Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016

Figure 12: Unmet Needs and Opportunities in DES

Figure 13: Bullseye Diagram of Products in Clinical Development for DES, 2016

Figure 14: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for DES in the 8MM During the Forecast Period

Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of DES During the Forecast Period

Figure 16: Analysis of the Company Portfolio Gap in DES During the Forecast Period

Figure 17: Global (8MM) Sales Forecast by Country for DES in 2016 and 2026

Figure 18: Sales Forecast by Class for DES in the US in 2016 and 2026

Figure 19: Sales Forecast by Class for DES in the 5EU in 2016 and 2026

Figure 20: Sales Forecast by Class for DES in Japan in 2016 and 2026

Figure 21: Sales Forecast by Class for DES in China in 2016 and 2026